![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ZNF92 |
Gene summary for ZNF92 |
![]() |
Gene information | Species | Human | Gene symbol | ZNF92 | Gene ID | 168374 |
Gene name | zinc finger protein 92 | |
Gene Alias | HEL-203 | |
Cytomap | 7q11.21 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q03936 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
168374 | ZNF92 | S029 | Human | Liver | HCC | 5.93e-29 | 1.32e+00 | 0.2581 |
168374 | ZNF92 | male-WTA | Human | Thyroid | PTC | 4.07e-02 | 1.96e-02 | 0.1037 |
168374 | ZNF92 | PTC01 | Human | Thyroid | PTC | 1.53e-06 | -1.21e-02 | 0.1899 |
168374 | ZNF92 | PTC05 | Human | Thyroid | PTC | 3.00e-09 | 1.93e-01 | 0.2065 |
168374 | ZNF92 | PTC06 | Human | Thyroid | PTC | 9.91e-05 | 1.74e-01 | 0.2057 |
168374 | ZNF92 | PTC07 | Human | Thyroid | PTC | 1.34e-11 | 9.21e-02 | 0.2044 |
168374 | ZNF92 | ATC11 | Human | Thyroid | ATC | 3.39e-02 | 1.86e-01 | 0.3386 |
168374 | ZNF92 | ATC13 | Human | Thyroid | ATC | 2.48e-58 | 1.19e+00 | 0.34 |
168374 | ZNF92 | ATC2 | Human | Thyroid | ATC | 2.48e-07 | 5.00e-01 | 0.34 |
168374 | ZNF92 | ATC3 | Human | Thyroid | ATC | 2.65e-03 | 1.71e-01 | 0.338 |
168374 | ZNF92 | ATC5 | Human | Thyroid | ATC | 4.13e-66 | 1.29e+00 | 0.34 |
Page: 1 2 3 4 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZNF92 | SNV | Missense_Mutation | c.1166N>C | p.Arg389Thr | p.R389T | Q03936 | protein_coding | tolerated(0.15) | possibly_damaging(0.647) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
ZNF92 | SNV | Missense_Mutation | novel | c.353A>C | p.Lys118Thr | p.K118T | Q03936 | protein_coding | tolerated(0.1) | benign(0.077) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ZNF92 | SNV | Missense_Mutation | c.1628N>G | p.Asp543Gly | p.D543G | Q03936 | protein_coding | tolerated(1) | benign(0.003) | TCGA-C5-A1BI-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
ZNF92 | SNV | Missense_Mutation | rs377733062 | c.463N>T | p.His155Tyr | p.H155Y | Q03936 | protein_coding | tolerated(0.25) | benign(0.026) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ZNF92 | SNV | Missense_Mutation | c.341G>A | p.Arg114Lys | p.R114K | Q03936 | protein_coding | tolerated(0.45) | benign(0.013) | TCGA-JX-A3Q0-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
ZNF92 | SNV | Missense_Mutation | c.277N>T | p.Asp93Tyr | p.D93Y | Q03936 | protein_coding | deleterious(0.04) | benign(0.062) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
ZNF92 | SNV | Missense_Mutation | rs781442558 | c.1423N>A | p.His475Asn | p.H475N | Q03936 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
ZNF92 | SNV | Missense_Mutation | novel | c.579N>C | p.Lys193Asn | p.K193N | Q03936 | protein_coding | tolerated(0.08) | benign(0.348) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ZNF92 | SNV | Missense_Mutation | novel | c.1059N>A | p.Phe353Leu | p.F353L | Q03936 | protein_coding | tolerated(0.43) | benign(0.013) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ZNF92 | SNV | Missense_Mutation | novel | c.467N>C | p.Lys156Thr | p.K156T | Q03936 | protein_coding | deleterious(0.03) | benign(0.117) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |